Targeted alpha therapy (TAT) combines an alpha emitting radioisotope with an appropriate
biological targeting molecule to selectively bind to cancer cells and deliver highly localised …

Objective. 225Ac radiopharmaceuticals have tremendous potential for targeted alpha
therapy (TAT), however, 225Ac (t1/2= 9.9 d) lacks direct gamma emissions for in vivo …

Among the growing list of alpha-emitting isotopes now available for pharmaceutical
development, Ac-225 can act as an in vivo alpha-generator radionuclide and is of great …

Objective. The development of alpha-emitting radiopharmaceuticals using 225 Ac (t ½= 9.92
d) benefits from the quantitative determination of its biodistribution and is not always easy to …

2341 Introduction: The development of alpha-emitting radiopharmaceuticals using 225 Ac (t
½= 9.9 d) requires quantitative determination of its biodistribution. SPECT imaging of the …

This review provides a general overview of the current achievements and challenges in
translational dosimetry for targeted alpha therapy (TAT). The concept of targeted …

P107 Introduction: 226 Ac (t 1/2= 29 h) has been proposed as a potential surrogate isotope
for the development of 225 Ac (t 1/2= 9.9 d) radiopharmaceuticals for targeted alpha therapy …

Abstract Background Actinium‐225 (225Ac) is an alpha emitting radionuclide which has
demonstrated promising results in Targeted Alpha Therapy (TAT). A concern with 225Ac is …

242536 Introduction: Actinium-225 (Ac-225) is emerging as a promising candidate for
targeted alpha therapy [1], necessitating the important need for methods to quantify …

ABSTRACT α-particle targeted radionuclide therapy has shown promise for optimal cancer
management, an exciting new era for brachytherapy. Alpha-emitting nuclides can have …